{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T02:05:54Z","timestamp":1784340354571,"version":"3.55.0"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T00:00:00Z","timestamp":1758499200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Immune checkpoint inhibitors (ICIs)-related pancreatitis is a rare but serious immune-related adverse event (AEs). This study aimed to investigate the risk and profile of ICIs-related pancreatitis on a real world setting by analyzing the FDA Adverse Event Reporting System (FAERS) data.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Data were extracted from the FAERS database from the first quarter of 2011 to the third quarter of 2024. Descriptive analysis was used to represent the clinical features, while reporting odds ratio (ROR), proportional reported ratio (PRR), the Bayesian confidence propagation neural network (BCPNN) and the multiple Gamma Poisson Shrinker (MGPS) were used for disproportionation analysis. The time to onset (TTO) was determined by calculating the interval between pancreatitis AEs and drug initiation time.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 1166 cases with positive signals for ICIs-related pancreatitis were screened, involving atezolizumab, durvalumab, avelumab, tislelizumab, pembrolizumab, nivolumab and ipilimumab. There were significant differences in the distribution of gender, weight, age, reporter, reporting country among all ICIs (<jats:italic>P<\/jats:italic> &amp;lt; 0.001). As for outcomes, 162 (14.1%) patients died. Avelumab had the highest incidence of death. The results of all four algorithms were consistent, indicating a statistically significant association between overall ICIs and the risk of pancreatitis (ROR 2.44, 95%CI 2.30 - 2.58; PRR 2.43, \u03c7<jats:sup>2<\/jats:sup> 979.71; EBGM 2.43, EBGM05 2.29; IC 1.28, IC025 1.22). The ICIs with the highest risk of developing pancreatitis were durvalumab, tislelizumab and avelumab. Avelumab has no significant correlation with pancreatitis in female and patients &amp;lt;65\u00a0years old, while other ICIs showed a correlation with pancreatitis, regardless of gender and age. For 491 reports which TTO data were available, the median TTO of ICIs-related pancreatitis was 59.0\u00a0days. The TTO of pancreatitis caused by each ICI was statistically significant (<jats:italic>P<\/jats:italic> = 0.0029). Ipilimumab had the shortest TTO of 37.5 days, while tislelizumab had the longest TTO of 146.5\u00a0days. The stratified analysis by gender and age showed that there was no significant difference in TTO.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>ICIs may have a significant association with the occurrence of pancreatitis. In clinical applications, it is necessary to closely monitor the indicators related to pancreatitis in patients, such as abdominal pain, nausea, vomiting, elevated serum amylase or lipase, and take timely intervention measures to reduce the risk of complications.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2025.1635372","type":"journal-article","created":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T07:12:42Z","timestamp":1758525162000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Pancreatitis associated with immune checkpoint inhibitors: a pharmacovigilance analysis based on FDA adverse event reporting system (FAERS) database"],"prefix":"10.3389","volume":"16","author":[{"given":"Lingli","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haitian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e19764","DOI":"10.7759\/cureus.19764","article-title":"A clinical overview of acute and chronic pancreatitis: the medical and surgical management","volume":"13","author":"Ashraf","year":"2021","journal-title":"Cureus"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e473080","DOI":"10.1200\/EDBK-25-473080","article-title":"Connecting the dots: Practical strategies for academic and Community oncology synergy to advance multidisciplinary management in immunotherapy toxicity care","volume":"45","author":"Brazel","year":"2025","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1007\/s00262-008-0642-y","article-title":"Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases","volume":"58","author":"Di Giacomo","year":"2009","journal-title":"Cancer Immunol. Immunother."},{"key":"B4","doi-asserted-by":"publisher","first-page":"A167","DOI":"10.1136\/ejhpharm-2020-eahpconf.356","article-title":"5PSQ-039 Pancreatitis induced by immunotherapy? Two case reports","volume":"27","author":"Dom\u00ednguez Bachiller","year":"2020","journal-title":"Eur. J. Hosp. Pharm."},{"key":"B5","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.annemergmed.2018.04.019","article-title":"Adverse effects of immune checkpoint therapy in cancer patients visiting the emergency department of a comprehensive cancer center","volume":"73","author":"El Majzoub","year":"2019","journal-title":"Ann. Emerg. Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1426847","DOI":"10.3389\/fphar.2025.1426847","article-title":"Immune checkpoint inhibitors-induced pancreatitis: a systematic review and real-world pharmacovigilance analysis","volume":"16","author":"Fang","year":"2025","journal-title":"Front. Pharmacol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.pan.2019.04.015","article-title":"Incidence of pancreatitis with the use of immune checkpoint inhibitors (ICI) in advanced cancers: a systematic review and meta-analysis","volume":"19","author":"George","year":"2019","journal-title":"Pancreatology"},{"key":"B8","doi-asserted-by":"publisher","first-page":"100042","DOI":"10.1016\/j.esmoop.2020.100042","article-title":"A prospective cohort study on the safety of checkpoint inhibitors in older cancer patients - the ELDERS study","volume":"6","author":"Gomes","year":"2021","journal-title":"ESMO Open"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e180516","DOI":"10.1172\/JCI180516","article-title":"Body mass index and adiposity influence responses to immune checkpoint inhibition in endometrial cancer","volume":"134","author":"G\u00f3mez-Banoy","year":"2024","journal-title":"J. Clin. Invest"},{"key":"B10","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s00262-020-02663-z","article-title":"Body mass index and immune-related adverse events in patients on immune checkpoint inhibitor therapies: a systematic review and meta-analysis","volume":"70","author":"Guzman-Prado","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann. Oncol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s40425-019-0502-7","article-title":"Clinical characteristics and outcomes of immune checkpoint inhibitor-induced pancreatic injury","volume":"7","author":"Hamzah","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"B13","first-page":"727","article-title":"PD-1\/PD-L1 pathway: current researches in cancer","volume":"10","author":"Han","year":"2020","journal-title":"Am. J. Cancer Res."},{"key":"B14","doi-asserted-by":"publisher","first-page":"e00667","DOI":"10.14309\/ctg.0000000000000667","article-title":"Incidence of pancreatic injury and pancreatitis in patients treated with immune checkpoint inhibitors","volume":"15","author":"Hori","year":"2024","journal-title":"Clin. Transl. Gastroenterol."},{"key":"B15","first-page":"113","article-title":"Two cases of autoimmune pancreatitis with diabetes and literature review","volume":"41","author":"Jia","year":"2020","journal-title":"Neuro Endocrinol. Lett."},{"key":"B16","doi-asserted-by":"publisher","first-page":"e53","DOI":"10.1097\/MPA.0000000000001107","article-title":"Anti-PD-1 drug (nivolumab) may induce acute and life-threatening pancreatitis in lung cancer patient: a case report","volume":"47","author":"Jiang","year":"2018","journal-title":"Pancreas"},{"key":"B17","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1097\/CJI.0000000000000472","article-title":"Immune checkpoint inhibitor-related pancreatitis: a case series, review of the literature and an expert opinion","volume":"46","author":"Kramer","year":"2023","journal-title":"J. Immunother."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.3390\/cancers17071080","article-title":"Immune checkpoint inhibitor-induced pancreatic injury (ICI-PI) in adult cancer patients: a systematic review and meta-analysis","volume":"17","author":"Lee","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B19","doi-asserted-by":"publisher","first-page":"109437","DOI":"10.1016\/j.biopha.2019.109437","article-title":"Diagnosis and management of immune related adverse events (irAEs) in cancer immunotherapy","volume":"120","author":"Liu","year":"2019","journal-title":"Biomed. Pharmacother."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14740338.2024.2446422","article-title":"Fulminant type 1 diabetes mellitus: a neglected but high-risk adverse event associated with immune checkpoint inhibitors","author":"Meng","year":"2024","journal-title":"Expert Opin. Drug Saf."},{"key":"B21","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1007\/s00535-024-02083-1","article-title":"Pancreatic injury in patients treated with immune checkpoint inhibitors: a retrospective multicenterstudy","volume":"59","author":"Nagao","year":"2024","journal-title":"J. Gastroenterol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1093\/annonc\/mdv383","article-title":"Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies","volume":"26","author":"Naidoo","year":"2015","journal-title":"Ann. Oncol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"763","DOI":"10.3390\/healthcare10050763","article-title":"Clinical characteristics of ICI-related pancreatitis and cholangitis including radiographic and endoscopic findings","volume":"10","author":"Nakano","year":"2022","journal-title":"Healthc. (Basel)"},{"key":"B24","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s00228-024-03647-z","article-title":"Immune-related serious adverse events with immune checkpoint inhibitors: systematic review and network meta-analysis","volume":"80","author":"Oliveira","year":"2024","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"3259","DOI":"10.3390\/curroncol28050283","article-title":"Safety of immune checkpoint inhibitors in elderly patients: an observational study","volume":"28","author":"Paderi","year":"2021","journal-title":"Curr. Oncol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1007\/s10637-025-01517-8","article-title":"Retrospective analysis of clinical features of nivolumab-induced immune-related pancreatitis","volume":"43","author":"Pan","year":"2025","journal-title":"Invest New Drugs"},{"key":"B27","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41572-020-0160-6","article-title":"Immune-related adverse events of checkpoint inhibitors","volume":"6","author":"Ramos-Casals","year":"2020","journal-title":"Nat. Rev. Dis. Prim."},{"key":"B29","doi-asserted-by":"publisher","first-page":"733","DOI":"10.2217\/imt-2018-0053","article-title":"Do immune checkpoint inhibitors perform identically in patients with weight extremes?","volume":"10","author":"Rassy","year":"2018","journal-title":"Immunotherapy"},{"key":"B30","doi-asserted-by":"publisher","first-page":"49","DOI":"10.6004\/jadpro.2020.11.1.3","article-title":"Management of acute pancreatitis associated with checkpoint inhibitors","volume":"11","author":"Rogers","year":"2020","journal-title":"J. Adv. Pract. Oncol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1097\/MOG.0000000000000873","article-title":"Type 3 autoimmune pancreatitis (immune checkpoint inhibitor-induced pancreatitis)","volume":"38","author":"Sayed Ahmed","year":"2022","journal-title":"Curr. Opin. Gastroenterol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"791","DOI":"10.2169\/internalmedicine.1943-23","article-title":"Immune checkpoint inhibitor-induced pancreatitis with pancreatic enlargement mimicking autoimmune pancreatitis: a case report and review of the literature","volume":"63","author":"Tanabe","year":"2024","journal-title":"Intern Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"339","DOI":"10.4143\/crt.2020.790","article-title":"The pattern of time to onset and resolution of immune-related adverse events caused by immune checkpoint inhibitors in cancer: a pooled analysis of 23 clinical trials and 8,436 patients","volume":"53","author":"Tang","year":"2021","journal-title":"Cancer Res. Treat."},{"key":"B34","doi-asserted-by":"publisher","first-page":"582","DOI":"10.6004\/jnccn.2024.0057","article-title":"NCCN Guidelines\u00ae insights: management of immunotherapy-related toxicities, version 2.2024","volume":"22","author":"Thompson","year":"2024","journal-title":"J. Natl. Compr. Canc Netw."},{"key":"B35","doi-asserted-by":"publisher","first-page":"3905","DOI":"10.2169\/internalmedicine.7366-21","article-title":"Fatal immune checkpoint inhibitor-related pancreatitis","volume":"60","author":"Ueno","year":"2021","journal-title":"Intern Med."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1177\/10781552211028636","article-title":"Two different immune related adverse events occurred at pancreas after nivolumab in an advanced RCC patient","volume":"28","author":"Yilmaz","year":"2022","journal-title":"J. Oncol. Pharm. Pract."},{"key":"B38","doi-asserted-by":"publisher","first-page":"e116","DOI":"10.2337\/dc18-2518","article-title":"T-lymphocyte infiltration to islets in the pancreas of a patient who developed type 1 diabetes after administration of immune checkpoint inhibitors","volume":"42","author":"Yoneda","year":"2019","journal-title":"Diabetes Care"},{"key":"B39","doi-asserted-by":"publisher","first-page":"817662","DOI":"10.3389\/fphar.2022.817662","article-title":"Pancreatic adverse events associated with immune checkpoint inhibitors: a large-scale pharmacovigilance analysis","volume":"13","author":"Zhang","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1166299","DOI":"10.3389\/fimmu.2023.1166299","article-title":"Pancreatic adverse events of immune checkpoint inhibitors therapy for solid cancer patients: a systematic review and meta-analysis","volume":"14","author":"Zhao","year":"2023","journal-title":"Front. Immunol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1338902","DOI":"10.3389\/fphar.2024.1338902","article-title":"Adverse drug events associated with linezolid administration: a real-world pharmacovigilance study from 2004 to 2023 using the FAERS database","volume":"15","author":"Zou","year":"2024","journal-title":"Front. Pharmacol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1635372\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T07:12:45Z","timestamp":1758525165000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1635372\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,22]]},"references-count":41,"alternative-id":["10.3389\/fphar.2025.1635372"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1635372","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,22]]},"article-number":"1635372"}}